Vslick, If Abbott was intending to commercialize RECAF, it is mandatory that they pay BioCurex a feasibility milestone. As of the latest filing, that milestone has NOT been paid.
After 4 1/2 years including an amendment that gave Abbott $50,000 and included a statement that abbott would no longer have any obligation to commercialize RECAF whatsoever and the fact that Abbott has never even paid the feasibility milestone, you can logically conclude that Abbott is no longer working on RECAF regardless of what anyone else pumping the stock attempts to tell you.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.